Keyphrases
Melanoma
100%
Melanoma Treatment
100%
Historical Precedents
100%
Immune Response
66%
Cancer Immunotherapy
66%
Ipilimumab
33%
Cancer Development
33%
Immunotherapeutics
33%
Future Therapies
33%
Current Therapies
33%
US FDA
33%
Targets for Therapy
33%
CTLA-4 Inhibitors
33%
Patient Stratification
33%
Stratification Criteria
33%
Immunology and Microbiology
Immunotherapy
100%
Cancer Immunotherapy
100%
Immune Response
50%
Immunity
50%
Ipilimumab
50%
Cytotoxic T Lymphocyte Antigen 4 Antibody
50%
Medicine and Dentistry
Nodular Melanoma
100%
Immunotherapy
100%
Cancer Immunotherapy
50%
Immune Response
25%
Ipilimumab
25%
Immunity
25%
Cytotoxic T Lymphocyte Antigen 4 Antibody
25%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Immunotherapy
100%
Malignant Neoplasm
50%
Ipilimumab
25%
Cytotoxic T Lymphocyte Antigen 4 Antibody
25%